The effect of intranasal corticosteroids on chronic idiopathic urticaria

Phase 3

Recruiting

Conditions: Idiopathic urticaria.
L50.1
Idiopathic urticaria

Registration Number: IRCT20231229060563N1

Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 69

Inclusion Criteria

Patients must be older than eighteen years.
Patients must have a diagnosis of idiopathic urticaria and positive prick test results for airborne antigens.
Patients must choose from adult allergy clinics and declare their informed consent to participate in the study.

Exclusion Criteria

Patients who are under treatment other than antihistamines by a doctor specializing in asthma and allergies.
Patients who cannot participate during six months.
Patients who had serious side effects due to corticosteroids before the start of the study.
Patients who have serious side effects caused by the use of corticosteroids during the study period.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome measures include the frequency and severity of urticaria symptoms, which are evaluated using valid scoring systems such as the Urticaria Activity Score and the Urticaria Severity Score. Timepoint: At the beginning of the study (before the start of the intervention) and six months after the start of corticosteroid use. Method of measurement: Urticaria severity and activity questionnaire.

Secondary Outcome Measures

Name	Time	Method
Secondary outcome measures will include the impact of urticaria on quality of life and daily activities, which will be evaluated using age-appropriate validation questionnaires. Timepoint: At the beginning of the study (before the start of the intervention) and six months later. Method of measurement: Questionnaire of the effect of urticaria on the quality of life.